Wilke H, Preusser P, Stahl M, Harstrick A, Meyer H J, Achterrath W, Schmoll H J, Seeber S
Department of Internal Medicine (Cancer Research), Essen University Medical School, Federal Republic of Germany.
Cancer Chemother Pharmacol. 1991;29(1):83-4. doi: 10.1007/BF00686342.
A group of 20 patients with gastric cancer, refractory to or with no change after two or three cycles of carboplatin were treated with etoposide/folinic acid/5-fluorouracil (ELF). An objective remission rate of 45% (9/20), a median remission duration of 8 months and a median survival time of 11 months were achieved. Toxicities were mild to moderate only. These results are comparable to those being achieved with ELF in previously untreated gastric cancer patients and confirm its efficacy and good tolerability.
一组20例胃癌患者，在接受两或三个周期的卡铂治疗后病情难治或无变化，接受了依托泊苷/亚叶酸钙/5-氟尿嘧啶（ELF）治疗。客观缓解率为45%（9/20），中位缓解持续时间为8个月，中位生存时间为11个月。毒性仅为轻至中度。这些结果与在先前未治疗的胃癌患者中使用ELF所取得的结果相当，证实了其疗效和良好的耐受性。
